Biocon shares jump 7% on strong Q4, dividend declaration
Biocon declared a dividend of ₹1.50 per share for FY23, which includes payout on account of one-time exceptional gains arising from partial monetisation of its holdings in Syngene
kiran mazumdar shaw
May 2023
March 2023
November 2022
October 2022
July 2022
February 2022
January 2022
November 2021
Kiran Mazumdar-Shaw retires from Infosys board
The board of India's second-largest software services firm has appointed D. Sundaram as the lead independent director with effect from March 23.
Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
Biocon stock tumbles 12% in 5 sessions; here’s why
Biocon shares declined as much as 2.4% to ₹262.40 on Wednesday, hitting its lowest level since November 2019.
HCL's Roshni Nadar Malhotra India’s richest woman; net worth ₹84,330 cr
Falguni Nayar of Nykaa is 2nd richest, with net worth of ₹57,520 cr; she’s also India's richest self-made woman, shows 'Leading Wealthy Women 2021' report by Hurun India, Kotak Private Banking
Bold bet! Biocon Biologics buys Viatris biosimilars assets for $3.33 billion
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
Covid-19 put spotlight on vaccines, diagnostics: Mazumdar-Shaw
Resurgence of interest and new technologies bring a huge opportunity for the vaccine development field, says Biocon CMD Kiran Mazumdar-Shaw.
Biocon developing 20 biosimilar products for global markets
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
Lift Covid restrictions, allow people to get back to life: Mazumdar-Shaw
The Biocon executive chairperson said curfews and lockdowns makes no sense as they have not proven helpful in curbing this pandemic.
Walgreens to sell Biocon's insulin Semglee in the U.S.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.
